Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases with its lead product, RP-G28, being developed for the treatment of lactose intolerance, today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a price to the public of $5.00 per share. All of the common stock is being offered by Ritter Pharmaceuticals, Inc. The gross proceeds to Ritter Pharmaceuticals, Inc. from the initial public offering are expected to be $20,000,000 before deducting underwriting discounts and commissions and other estimated offering expenses.
Ritter Pharmaceuticals, Inc. has granted the underwriters a 45-day option to purchase up to 600,000 additional shares of common stock to cover over-allotments, if any. The common stock of Ritter Pharmaceuticals, Inc. has been approved for listing on The NASDAQ Capital Market and is expected to begin trading under the ticker symbol "RTTR" on June 24, 2015. The offering is expected to close on June 29, 2015, subject to customary closing conditions.
Aegis Capital Corp. is acting as sole book-running manager for the offering.
Chardan Capital Markets, LLC is acting as lead manager and Barrington Research is acting as co-manager for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission and declared effective on June 24, 2015.
Ritter Pharmaceuticals, Inc. has granted the underwriters a 45-day option to purchase up to 600,000 additional shares of common stock to cover over-allotments, if any. The common stock of Ritter Pharmaceuticals, Inc. has been approved for listing on The NASDAQ Capital Market and is expected to begin trading under the ticker symbol "RTTR" on June 24, 2015. The offering is expected to close on June 29, 2015, subject to customary closing conditions.
Aegis Capital Corp. is acting as sole book-running manager for the offering.
Chardan Capital Markets, LLC is acting as lead manager and Barrington Research is acting as co-manager for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission and declared effective on June 24, 2015.
Text zur Anzeige gekürzt. Gesamten Beitrag anzeigen »
